Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Intel’s Comeback Conundrum: Will INTC Stock Soar or Stumble in 2024?

Intel (NASDAQ:INTC) used to be the undisputed leader in chip-making. However, the 2020s have not been so kind. AMD started gaining CPU market share against Intel during the pandemic years and they quickly got better–in terms of value–to the point where Intel was in serious danger of losing its CPU market leadership to AMD. It still is, but the CPU market has been on the backburner since AI started taking over.

AMD was already trouble enough for Intel, and the stock traded around $27 to $30 for a few months before ChatGPT’s release gave investors enough optimism to push it higher–at least for a while before they realized the competition Intel was facing in the AI field. The rising tide mostly lifted Nvidia–including some AI pick-and-shovel AI stocks–and AMD to some extent. It’d be appropriate to say that Intel basically drowned in the tide.

It went from being the go-to semiconductor stock to a legacy company playing catch-up.

Now, it’s impossible to discuss any of the big chip stocks without talking about Nvidia. Nvidia has always been making the best GPUs, and it found itself in a perfect spot to capitalize when the AI chip market ballooned–and ballooned it did. If anyone talks about chips nowadays–outside of niche circles–they’re probably talking about ones that are meant for AI usage. AI chips include graphics processing units (GPUs), field-programmable gate arrays (FPGAs), and application-specific integrated circuits (ASICs). They also use CPUs to some extent, but it’s becoming irrelevant as AI models and chips get better. Intel has been making “AI chips” for a while, but they’ve always been behind in this regard. Intel’s main focus was always the CPU market, and they doubled down on it as AMD started to eat more market share. Then, they changed gears again during the AI boom and they’re now trying to catch up with Nvidia and AMD.

Pat Gelsinger’s arrival as CEO in 2021 was supposed to be the turning point—a man returning to save the company he once helped build. His “IDM 2.0” strategy promised a renaissance, with plans to invest billions in manufacturing capabilities and reclaim technological leadership. But promises and reality have been two very different things so far.

That’s basically how Intel has gotten to where it’s at. The stock is at $24 as of writing and is up 30% from its trough. Can it go up from here, or will this rally die out just like it did during the start of the year? We’re going to have to dig deeper than that. Let’s start with the most critical aspect: understanding the business itself.

How Intel’s Business Works

Intel’s business is structured around two main pillars: Intel Products and Intel Foundry. They also own Altera, Mobileye, and some other companies. Here’s a quick glance into how they performed in Q3:

Let’s talk about Products first.

Intel Products is divided into three groups: Client Computing Group (CGC), Data Center and AI (DCAI), and Network and Edge (NEX).

Client Computing Group (CGC): This is Intel’s bread and butter. It contributed $7.3 billion of Intel’s $13.3 billion Q3 revenue. It’s what most people associate with Intel–the Core processors, for example.

Intel’s flagship product line includes the Core i3, i5, i7, and i9 processors. It has also been selling AI PCs. They are a new generation of PCs that are more fine-tuned for AI and have a neural processing unit (NPU) to handle AI models locally. Intel has shipped over 15 million AI PCs powered by its latest Core Ultra processors. They’re targeting 40 million by the end of 2024 and over 100 million by the end of 2025. The CCG also includes adjacent products such as modems, Bluetooth, and Wi-Fi technologies.

Data Center and AI (DCAI): The DCAI group is where Intel competes in the high-performance computing space. In Q3 2024, this segment generated $3.3 billion in revenue. This is a 9% increase from the previous quarter. This growth is mainly driven by the demand for data center solutions. Xeon processors have long been the standard for data centers worldwide. The next-generation Xeon processors—Sierra Forest (E-cores) and Granite Rapids (P-cores)—are set to launch in 2024 and 2025 respectively.

In addition to Xeon CPUs, Intel has been developing its own AI-specific hardware with the launch of its Gaudi 3 AI accelerator. It promises to deliver twice the performance per dollar compared to Nvidia when it comes to both inference and training AI models.

Network and Edge Group (NEX): The NEX group focuses on networking hardware and edge computing solutions—areas that are becoming increasingly important as more devices are connected through IoT (Internet of Things) networks. NEX generated $1.5 billion in Q3 2024. One of NEX’s most notable contributions is its range of Ethernet solutions optimized for AI. Intel also has infrastructure processing units (IPUs) that help offload networking tasks from CPUs in data centers. These products are essential as more businesses adopt edge computing to process data closer to where it is generated.

Now, let’s look into Intel Foundry Services.

IFS wants to manufacture not just Intel’s own chips but also for external customers. Intel isn’t as reliant on external semiconductor manufacturers as some other fabless companies, so they’re trying to put this manufacturing capacity to good use. It has a plan called “five nodes in four years,” which aims to catch up with competitors like TSMC. The most significant milestone here is the development of their cutting-edge process node—Intel 18A, which is expected to be production-ready by late 2025. IFS has already secured several high-profile customers interested in using its advanced packaging technologies like EMIB (Embedded Multi-die Interconnect Bridge).

As I said before, Intel also owns Mobileye and Altera. Mobileye makes driver assist technology; Alteryx does data analytics.

How has Intel Been Doing Financially?

If I were to put it simply: not so well.

Revenue was down 6% year-over-year at $13.3 billion. This decline was driven by a 7% drop in CCG revenue and a staggering 79% plunge in external foundry revenue, even though DCAI managed a 9% uptick.

Profitability took an even harder hit. Gross margins plummeted to a dismal 15% against the 42.5% reported in Q3 2023. The company attributed this primarily to “non-cash impairments and the acceleration of depreciation for certain manufacturing assets, a substantial majority of which related to our Intel 7 process node.” Adding insult to injury, the company posted a net loss of $16.6 billion; this loss is a sharp reversal from the $297 million profit the same quarter last year. This translates to a diluted loss per share of $3.88. Ouch.

This poor performance wasn’t confined to just Q3. If you zoom out, the debt and the cash flow trends are very bearish. It will likely continue to be this way as Intel spends more on catching up.

The nine-month figures for 2024 are also troubling. While revenue year-to-date (YTD) is roughly flat compared to the same period in 2023 at $38.8 billion, profitability and earnings are severely down. YTD gross margin is 30.3% (down from 37.8% in 2023), operating income has swung to a $12 billion loss, and the company has a net loss of $18.6 billion.

Cash flow has also deteriorated. Q3 operating cash flow declined 25% YoY to $5.1 billion and adjusted free cash flow remains deeply negative at $(0.7) billion. While the company continues to tout its IDM 2.0 strategy, its high capital expenditure needs (CapEx was $17.3 billion for the nine months ended Q3 2024), and ambitious plans to ramp up foundry services, coupled with soft demand and product delays have made generating significant positive cash flow difficult to achieve.

These challenges clearly raise concerns about the timeline and ultimate success of Gelsinger’s turnaround plan. Whether Intel can reclaim process leadership with its “five nodes in four years” objective and execute the IFS strategy remains open to question in the wake of continued weak financial results. The significant valuation allowance of $9.9 billion against net deferred tax assets–indicating the likelihood the tax assets will not be able to be used–recorded by the company in Q3 further complicates investor sentiment for the future of the business.

Accounting Standards Codification (ASC) 740 requires companies to reduce a deferred tax asset if there’s more than a 50% chance that asset won’t be realized “based on the weight of available evidence.” This $9.9 billion allowance means that–more likely than not–Intel isn’t turning profitable enough anytime soon to use these tax benefits.

If Intel becomes highly profitable again, they can absolutely use these tax credits; they’re just required by accounting rules to mark them as unlikely to be used right now because they don’t see enough near-term profitability to take advantage of them. Accordingly, my takeaway is that we should not expect Intel to pull off the sharpest of turnarounds.

Is Intel Stock Undervalued?

INTC stock has a forward PE of 27 times and a PS ratio of 1.9 times. These appear somewhat modest compared to historical averages and some industry peers. However, these seemingly attractive multiples can be deceptive.

Intel is betting big on a long-term turnaround by focusing more on manufacturing its own chips instead of just designing and letting others do it. It may eventually improve its profit margins, but it’s a gamble right now; Intel could regain its glory or end up worse off.

Here’s what analysts see so far:

There’s a chance Intel with keep up with the revenue estimates, but I’m not so sure about EPS, as Intel has consistently been missing those. In essence, the top line has likely bottomed; the bottom line is the new issue. The foundry division posted significant losses, including a $5.8 billion loss in Q3 2024 alone. As I said before, Intel is betting on the long term, and you shouldn’t expect solid profits in the near term.

What impact will this have on the price going forward?

The average 12-month price target for INTC stock is around $24.43, with a range between $18 and $28. Analysts basically see no upside here–on average, of course–in the next twelve months.

If you’re betting on making money through dividends or buybacks–you shouldn’t. Dividend payouts are going down and outstanding shares are rising.

This is the opposite of what a mature company should be doing. But again, this is just Intel trying to catch up to Nvidia and AMD and regain growth. No one can tell whether or not all these investments will end up being worthwhile.

So, Is Intel Stock Undervalued? Nope.

If you take a look beyond the forward PE ratio and stop associating Intel with other high-growth AI companies, the shares are not too undervalued. Does that mean Intel doesn’t have upside from here? Absolutely not. Intel could still surprise analysts going forward or the market could slap a higher premium on it regardless. Here’s what I see based on my research:

Is this worth chasing? Depends on you. For me, I would say no. My argument is that Intel has gotten way too invested in the AI race to a point where it will suffer disastrous consequences if it doesn’t pay off, and if it does pay off, I’d probably get better returns from other AI chipmakers; they all have much healthier balance sheets and margins.

That said, if you’re into turnaround plays–as Peter Lynch would like to call them–an INTC investment could play out well in the long run if the bull case turns out to be correct.

While I acknowledge the potential of INTC as an AI play, my conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NVDA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: PLTR Stock: Genuine Growth or Just Hype? Let’s Take a Look. and AMZN Stock Popped After Q3 – Is It Too Late to Buy Amazon Now?

Disclosure: None.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!

Penicillin Changed the World. This Drug Could Too

This Clinical-stage Biotech Company is Taking a Revolutionary Approach to Eradicating Many Respiratory Viruses Including a single drug to treat COVID, RSV, FLU and even Monkey-pox!

This is a clinical-stage, global leader in broad-spectrum antiviral nanomedicines who is developing therapeutic drugs that work safely and effectively, even against emerging variants!

A novel broad-spectrum antiviral

NV-387,  a drug that  treats RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections as well as Monkey-pox, has successfully completed Phase 1 clinical trials in healthy subjects with no reported adverse events, even at the highest and repeated dosages. Remarkably, the company has been able to develop NV-387 for oral administration already, as well as for injectable and inhalation formulations to enable many modes of use. The Company is currently focused on advancing NV-387 into Phase II human clinical trials for the treatment of RSV infection.

Susceptible viruses CANNOT escape NV-387, even as they continue to evolve in the field into variants. Why? Because  no matter how much the virus changes, it continues to use the same host-side signature to bind to and cause infection in the hosts, and thus the nanoviricide would be anticipated to continue to be effective even as the virus mutates to generate variants.

Click to continue reading…